NEWS
Go back
ARCHIMED acquires generative AI Diagnostics player Arkstone to support fight against infectious disease
August
1,
2025
Private equity healthcare specialist ARCHIMED acquired a majority stake in Arkstone Medical Solutions (Arkstone), a pioneer in infectious disease clinical guidance and antimicrobial stewardship based on machine learning (ML) and generative artificial intelligence (gen AI).
Florida-based Arkstone was created in 2018 by three co-founders with backgrounds in software, clinical content, and customer operations. The company provides Clinical Decision Support powered by Machine Learning (ML) and generative Artificial Intelligence (gen AI), helping healthcare providers optimize antimicrobial use. Arkstone’s flagship OneChoice Report leverages ML and gen AI to provide optimal infectious disease treatment recommendations. OneChoice analyses laboratory results alongside patient data and delivers guidance to clinicians. Already in use by over 150 laboratories across the US and internationally, Arkstone is transforming how healthcare providers diagnose, treat, and understand infectious diseases.
Arkstone is at the junction of ARCHIMED’s Healthcare IT and Diagnostics sectors. It operates in a prioritized sub-sector identified thanks to ARCHIMED’s MedSeg tool. The investment opportunity was sourced directly by the team after being screened and identified as a category leader through ARCHIMED’s MedDiscover approach.
This transaction reflects ARCHIMED’s ability to respond to public health issues – which was already the case through its investment in Testing player CARSO.
ARCHIMED will work with management to accelerate the company’s development, through its MedValue playbook, ultimately bringing Arkstone’s technology to more clinicians around the world, democratizing infectious disease expertise and leading the fight against global antimicrobial resistance.
“This partnership marks a transformative milestone for Arkstone. ARCHIMED’s experience in supporting healthcare players and its global presence will significantly enhance our ability to innovate and bring life-saving antimicrobial stewardship solutions to a broader global audience.” said Ari Frenkel, MD, MPH, Chief Science Officer at Arkstone.
Through this investment, ARCHIMED confirms its ability to deploy across cycles with a broad sector diversification throughout healthcare industries. Arkstone represents the third investment of ARCHIMED’s MED Rise fund following SeqCenter (Diagnostics) and FIM Medical (Medtech).
“Backed by ARCHIMED’s capital, our support in innovation and internationalization, Arkstone is poised to scale its impact on the global fight against antimicrobial resistance, one of the most urgent public health threats of our time.”
Igor Petricca, Partner at ARCHIMED
MED Rise is ARCHIMED’s 2024 small-cap buyout fund. ARCHIMED can invest from €10 million to €1 billion per investment through its different fund lines.
All fully deployed ARCHIMED funds have top decile performance, especially from a DPI perspective (Source: PitchBook) and ARCHIMED was ranked as the world’s 6th best performing Buyout firm in the 2023 HEC-DowJones ranking (out of 632 Buyout firms globally).